查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984182

下一代生物製造市场：2026-2032年全球市场预测（依产品类型、技术、製程阶段、业务规模、细胞株、製程模式及最终用户划分）

Next-Generation Biomanufacturing Market by Product Type, Technology, Process Stage, Operation Scale, Cell Line, Process Mode, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计下一代生物製造市场在 2025 年的价值为 4.6622 亿美元，在 2026 年增长到 5.9443 亿美元，到 2032 年达到 26.2487 亿美元，复合年增长率为 28.00%。

主要市场统计数据
基准年 2025 4.6622亿美元
预计年份：2026年 5.9443亿美元
预测年份 2032 2,624,870,000 美元
复合年增长率 (%) 28.00%

本书权威地介绍了下一代生物製造技术，重点在于先进生物製药开发、模组化生产架构、人才策略和全球供应链韧性。

在生物製剂的快速发展、灵活的生产技术以及后疫情时代对韧性供应链的需求推动下，下一代生物製造正成为未来十年最重要的产业变革之一。本文概述指出，该领域不仅是现有製造能力的演进，更是治疗药物发现、生产和交付方式的系统性变革。在整个开发平臺中，研发人员正致力于开发日益复杂的治疗方法，包括细胞和基因疗法、重组蛋白、单株抗体和新型疫苗平台，这推动了对能够同时支援小批量、个人化生产和可扩展商业供应的生产架构的需求。

突破性的技术创新、监管变革和商业性变化如何重新定义全球生物製造能力、製程架构、资本配置和策略投资。

生物製造领域的格局正因技术创新、法规演变和商业策略的交会而重塑，并受到多项变革性变化的影响。首先，科技融合正在加速。连续生物製程和先进分析技术正与一次性硬体和模组化设施设计相结合，建构出兼具柔软性和高度自动化的系统。这种融合缩短了技术转移週期，减少了停留时间，并提高了品质特性的可预测性。随着製程的成熟，所有这些因素共同降低了操作的复杂性。

评估 2025 年美国关税措施对整个生物製造生态系统的原物料采购、契约製造经济、跨境供应链、资本配置和近岸外包决策的累积影响。

美国2025年实施的关税措施对整个生物製造生态系统产生了复杂且累积的影响，其影响远不止于直接的成本上涨。初期，关税将推高进口原料、一次性组件和专用设备的到货成本，促使采购团队重新评估其供应商组合和合约条款。随着时间的推移，这些增加的投入成本可能会改变采购週期，从而可能促使企业进行批量采购和签订长期供应合同，以对冲关税波动风险。因此，筹资策略正从现货采购转向能够提供价格稳定和技术合作的策略伙伴关係。

关键的细分洞察揭示了产品类型、底层技术、各个製程阶段、不同的最终用户、业务规模、细胞株选择和製程模式的细微差异如何决定产能投资和商业化策略。

一套精细的细分框架清楚地阐明了在产品类型、技术、製程阶段、最终用户、业务规模、细胞株和製程模式等方面，能力投资和策略重点在哪些领域能够产生最大影响。就产品类型而言，细胞和基因疗法需要独特的生产模式，包括CAR-T疗法、细胞疗法和基因编辑疗法，这些疗法对小批量、患者特异性的生产物流高度敏感。另一方面，酶的应用涵盖诊断和工业领域，在这些领域，通量和成本效益至关重要。单株抗体可分为自体免疫、感染疾病和肿瘤治疗应用，每种应用对效力和纯度的要求各不相同。重组蛋白，包括细胞激素、生长因子和激素，通常需要严格控制上游和下游工作流程。疫苗涵盖广泛的平台，包括活病毒疫苗、mRNA疫苗、次单位疫苗和病毒载体疫苗，每种疫苗都有其独特的低温运输和填充/表面处理工程。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和战略意义，对生物製造领导者的生产能力位置、监管协调、人才流动和跨境合作产生影响。

区域趋势是企业在决定生产能力位置、供应链结构和监管路径时进行策略决策的核心。在美洲，先进的临床生态系统、强劲的投资者兴趣和密集的供应商网络正在推动利基产品製造的发展，以实现快速商业化和个人化疗法。然而，供应链摩擦和政策不确定性仍然可能导致选择性近岸外包和更严格的供应商筛选。在欧洲、中东和非洲，监管协调和强有力的公私合营关係正在为大批量生技药品和疫苗生产创造极具吸引力的地点。然而，细微的区域监管差异需要製定针对特定区域的申请策略，并延长产品上市时间。

这提供了企业级的洞察，重点介绍了製药开发公司、契约製造製造商、技术提供商和系统整合商如何重组其产品组合、建立策略联盟以及优化其製造地以抓住机会。

生物製造价值链上的主要企业正透过产能扩张、策略伙伴关係和有针对性地采用新技术来适应不断变化的市场环境。契约製造正日益提供从细胞库和分析开发到商业规模填充和包装等一系列整合服务，以获取更大价值并加快客户的产品上市速度。技术供应商则专注于模组化、一次性产品和数位化平台，以实现远端监控和预测性维护，从而降低营运风险并支援多地点协作。製药研发公司则透过保留对细胞株开发和製程表征等关键流程的策略控制权，同时将常规的规模化生产和大规模生产外包给专业合作伙伴，来打造差异化优势。

为行业领导者提供可操作的策略建议，以加速采用先进的生物工艺，确保有韧性的供应链网络，使商业模式适应不断变化的法规，并优先考虑可扩展的投资以获得长期竞争优势。

在技​​术和政策快速变化的背景下，行业领导者应采取切实可行且优先级明确的行动，以保持竞争优势。首先，应加快采用模组化和一次性资产，用于早期和灵活的商业化生产，以缩短部署时间并减轻验证负担。这种方法使企业能够在有限的资本框架内试点创新製程模式，例如灌注培养和连续层析法，然后在产品经济效益证明大规模的固定投资合理时，选择性地扩大生产规模。其次，应实现供应商多元化，并加强策略采购协议，以减轻关税相关的成本波动，并最大限度地降低单一供应商失效的风险。同时，应制定紧急时应对计画，包括本地製造合作伙伴和检验的替代供应商。

这种高度透明的研究方法详细介绍了综合的一手和二手研究、专家访谈、数据检验、检验过程、细分映射和可重复的评估调查方法，以产生可靠的市场洞察。

本分析的调查方法采用综合方法，结合一手访谈、二手文献整合和严谨的检验，确保研究结果的稳健性和可重复性。一手研究包括对研发、製造、采购和监管部门高阶主管的结构化访谈，以及与技术供应商、系统整合商和契约製造的深入交流。这些交流揭示了技术转移和规模化生产中的实际限制、投资重点以及挑战实例。二手研究涵盖了同行评审文献、公开的监管指导文件和技术白皮书，以阐明发展趋势并检验技术论点。

对于希望在下一代生物製造领域占据主导的相关人员，这提供了简洁的策略结论，整合了关键点、必要的风险缓解措施、投资重点和前瞻性考虑因素。

总之，下一代生物製药代表着一个策略转折点，技术创新、供应链策略和监管调整在此交汇融合，重塑产业的经济结构和竞争力。连续生物製程、模组化设施、一次性系统和数位分析技术的成熟，为更快、更可靠地生产复杂生物製药铺平了道路，但要实现这些优势，需要对能力建设和伙伴关係关係进行审慎的投资。因此，领导者必须根据每种製程的具体需求调整资本配置，优先考虑供应商在面对地缘政治因素和关税波动时的韧性，并组成能够管理自动化、数据驱动型营运的跨职能团队。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 下一代生物製造市场：依产品类型划分

  • 细胞和基因治疗
    • CAR-T疗法
    • 细胞疗法
    • 基因编辑疗法
  • 酵素
    • 诊断酶
    • 工业酵素
  • 单株抗体
    • 自体免疫
    • 感染疾病
    • 肿瘤学
  • 重组蛋白
    • 细胞激素
    • 生长因子
    • 荷尔蒙
  • 疫苗
    • 减毒活病毒疫苗
    • 药效疫苗
    • 次单位疫苗
    • 病毒载体疫苗

第九章：下一代生物製造市场：依技术划分

  • 无细胞系统
    • 无细胞表现试剂盒
    • 无细胞合成平台
  • 连续生物工艺
    • 连续层析法
    • 在线连续监测系统
    • 灌注系统
  • 模组化设施
    • 预製模组
    • 滑座式系统
  • 免洗系统
    • 免洗袋子
    • 免洗生物反应器
    • 一次性软管和接头

第十章 依製程阶段分類的下一代生物製造市场

  • 下游工艺
    • 层析法
    • 过滤
    • 纯化
  • 配方
    • 填充和精加工
    • 冷冻干燥
    • 包装
  • 上游工程
    • 生物反应器运行
    • 细胞培养
    • 培养基製备

第十一章 按营运规模分類的下一代生物製造市场

  • 临床量表
  • 商业规模
  • 中试规模

第十二章细胞株系视野下的下一代生物製造市场

  • Cho 细胞
    • Cho-DG44
    • Cho-K1
  • 大肠桿菌
    • Bl21
    • K12
  • 酵母菌
    • 毕赤酵母
    • 酿酒酵母

第十三章 按製程模式分類的下一代生物製造市场

  • 批次
  • 连续型
  • 联邦批次
  • 灌注

第十四章 下一代生物製造市场：依最终用户划分

  • 学术和研究机构
  • 生技公司
  • 契约製造组织
  • 製药公司

第十五章 下一代生物製造市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 下一代生物製造市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 下一代生物製造市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国下一代生物製造市场

第十九章：中国的下一代生物製造市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Amyris, Inc.
  • Applikon Biotechnology BV
  • bbi-biotech GmbH
  • Biofluidica, Inc.
  • Codexis, Inc.
  • Danaher Corporation
  • Eppendorf AG
  • ESCO Group
  • Eurofins Scientific SE
  • Evolva Holding SA
  • Evonik Industries AG
  • GEA Group AG
  • GENEWIZ, Inc. by Azenta Life Sciences
  • Genomatica, Inc.
  • Ginkgo Bioworks Holdings, Inc.
  • Hamilton Company
  • Illumina, Inc.
  • Koninklijke DSM NV
  • LanzaTech, Inc.
  • Macrogen Inc.
  • Merck KGaA
  • Novozymes A/S
  • Oxford Nanopore Technologies plc
  • PBS Biotech, Inc.
  • PerkinElmer Inc.
  • QIAGEN NV
  • Sartorius AG
  • Shanghai Bailun Biotechnology Co., Ltd.
  • Solaris Biotechnology Srl by DONALDSON ITALIA SRL
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • ZETA GmbH
  • Zymergen Inc.
Product Code: MRR-5C6F41F5AFEF

The Next-Generation Biomanufacturing Market was valued at USD 466.22 million in 2025 and is projected to grow to USD 594.43 million in 2026, with a CAGR of 28.00%, reaching USD 2,624.87 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 466.22 million
Estimated Year [2026] USD 594.43 million
Forecast Year [2032] USD 2,624.87 million
CAGR (%) 28.00%

An authoritative introduction positioning next-generation biomanufacturing at the intersection of advanced biologics development, modular production architectures, workforce talent strategies, and global supply resilience

Next-generation biomanufacturing is emerging as one of the most consequential industrial transformations of the coming decade, propelled by rapid advances in biologics, flexible production technologies, and a post-pandemic imperative for resilient supply chains. This introduction frames the sector not merely as an evolution of existing manufacturing capabilities but as a systemic shift in how therapeutics are discovered, produced, and delivered. Across development pipelines, developers are pursuing increasingly complex modalities including cell and gene therapies, recombinant proteins, monoclonal antibodies, and novel vaccine platforms, driving demand for production architectures that can support small-batch personalization and scalable commercial supply concurrently.

Moreover, new manufacturing paradigms-such as modular facilities, single-use systems, continuous bioprocessing, and cell-free technologies-are enabling faster time-to-clinic, reduced capital intensity for initial capacity, and improved responsiveness to demand variability. Consequently, operational priorities now include rapid technology transfer, enhanced process analytics for inline monitoring, and workforce upskilling to manage programmable, highly automated operations. As stakeholders evaluate strategic options, this report positions the industry's trajectory in terms of capability buildout, competitive dynamics among developers and contract manufacturers, and the policy environments influencing cross-border supply. In doing so, it provides a structured foundation for leaders seeking to balance innovation speed, manufacturing reliability, and regulatory compliance.

How transformative technological innovations, regulatory recalibrations, and commercial shifts are collectively redefining biomanufacturing capacity, process architectures, capital allocation, and strategic investments worldwide

The landscape of biomanufacturing is being reshaped by several transformative shifts that intersect technological innovation, regulatory evolution, and commercial strategy. First, technological convergence is accelerating: continuous bioprocessing and advanced analytics are merging with single-use hardware and modular facility designs to produce systems that are both flexible and highly automated. This convergence shortens technology transfer cycles, reduces hold times, and enables more predictable quality attributes, which collectively lower operational complexity as processes mature.

Second, regulatory pathways are adapting to accommodate novel modalities and decentralized production models. In turn, regulators are placing greater emphasis on real-time release testing, risk-based validation approaches, and harmonization efforts that reduce duplication across markets. As a result, manufacturers that proactively invest in robust process characterization and digital quality architectures are increasingly positioned to gain regulatory latitude and accelerate time-to-patient.

Third, commercial models are evolving in response to demand fragmentation and premium pricing dynamics for personalized therapies. Contract development and manufacturing organizations will therefore take on greater responsibility for end-to-end program delivery, including integrated analytics, cell banking, and cold-chain logistics orchestration. Finally, strategic capital allocation is shifting toward platforms that offer rapid scalability-prefabricated modules and skid-mounted systems-enabling companies to respond to therapeutic breakthroughs and regional demand shifts with lower up-front risk. Together, these shifts are not isolated; they interact to create a new operational logic where speed, quality, and adaptability determine competitive advantage.

Assessing the cumulative effects of United States tariff actions in 2025 on raw material sourcing, contract manufacturing economics, cross-border supply chains, capital deployment, and nearshoring decisions across biomanufacturing ecosystems

United States tariff actions in 2025 have imposed a complex, cumulative set of effects across the biomanufacturing ecosystem, with implications that extend beyond immediate cost inflation. Initially, tariffs increase the landed cost of imported raw materials, single-use components, and specialized instrumentation, prompting sourcing teams to reassess supplier portfolios and contractual terms. Over time, those higher input costs alter procurement rhythms and may incentivize bulk purchasing or long-term supply agreements to hedge against tariff volatility. As a result, purchasing strategies are shifting from spot buys toward strategic relationships that offer price stability and technical collaboration.

In addition to direct cost impacts, tariffs reshape strategic decisions around localization and capacity siting. Facing persistent tariff risk, some organizations accelerate nearshoring or onshoring initiatives to reduce exposure to cross-border duties and to shorten supply chains. This movement influences capital deployment, as companies weigh the trade-offs between the higher initial capital required for localized facilities and the operational benefits of reduced border friction, shorter lead times, and improved control over quality-critical inputs. Conversely, regions that maintain open trade policies and competitive supplier ecosystems can attract outsourced production and enable multinational companies to centralize specialized manufacturing tasks.

Tariffs also interact with regulatory and logistical dynamics. Increased customs inspections and documentation requirements extend lead times for critical materials, amplifying the need for higher safety stock levels and more granular inventory management. Moreover, the cumulative effect of tariffs on specialized consumables and single-use components can accelerate investment in alternative technologies such as reusable bioreactors or local fabrication of ancillary equipment, where feasible. In sum, the 2025 tariff environment compels a more strategic orientation toward supplier diversification, resilience planning, and the re-evaluation of global footprint strategies for biomanufacturing stakeholders.

Key segmentation insights revealing how nuanced product types, enabling technologies, discrete process stages, varied end users, operational scales, cell line selections, and process modes determine capability investments and commercialization strategies

A nuanced segmentation framework clarifies where capability investments and strategic emphasis will be most consequential across product types, technologies, process stages, end users, operational scales, cell lines, and process modes. When looking across product types, cell and gene therapies demand unique manufacturing paradigms that include CAR-T therapies, cell therapies, and gene editing therapies with high sensitivity to small-batch, patient-specific production logistics, whereas enzymes span diagnostic and industrial use cases that prioritize throughput and cost efficiency. Monoclonal antibodies fragment into autoimmune, infectious disease, and oncology applications with divergent potency and purity needs. Recombinant proteins, including cytokines, growth factors, and hormones, typically require tightly controlled upstream and downstream workflows. Vaccines encompass a spectrum of platforms-live attenuated, mRNA, subunit, and viral vector vaccines-each of which imposes distinct cold-chain and fill-finish constraints.

Technological segmentation further underscores differences in capital allocation and operational design. Cell-free systems, whether sold as expression kits or integrated synthesis platforms, introduce options for decentralized manufacturing and rapid prototyping. Continuous bioprocessing elements-such as continuous chromatography, inline monitoring systems, and perfusion technologies-enable steady-state operations that reduce batch-to-batch variability. Modular facilities built from prefabricated modules or skid-mounted systems deliver faster commissioning, while single-use systems comprised of single-use bags, bioreactors, and tubing reduce cleaning validation burdens and cross-contamination risk. Process stage segmentation clarifies where value is created: upstream processing activities like bioreactor operation, cell culture, and media preparation set biological performance, while downstream processing through chromatography, filtration, and purification, together with formulation activities such as fill-and-finish, lyophilization, and packaging, determine final product stability and patient readiness.

End-user segmentation differentiates academic and research institutions, biotech companies, contract manufacturing organizations, and pharmaceutical companies as distinct decision-makers with varied priorities. Operation scale separates clinical, pilot, and commercial stages, each with its own tolerance for risk and capital intensity. Cell line choice-CHO cell variants like CHO-DG44 and CHO-K1, E. coli strains such as BL21 and K12, and yeast species including Pichia pastoris and Saccharomyces cerevisiae-influences expression yield, glycosylation profiles, and downstream purification strategies. Finally, process mode selection among batch, continuous, fed-batch, and perfusion determines facility layout, analytics needs, and staffing models. Integrating these segmentation lenses helps executives prioritize investments that align with modality-specific technical constraints and commercial trajectories.

Regional dynamics and strategic implications across the Americas, Europe Middle East and Africa, and Asia-Pacific that influence capacity siting, regulatory harmonization, talent migration, and cross-border collaboration for biomanufacturing leaders

Regional dynamics are central to strategic decision-making as companies decide where to locate capacity, how to structure supply chains, and which regulatory pathways to prioritize. In the Americas, the combination of advanced clinical ecosystems, robust investor interest, and a dense supplier network supports rapid commercialization and the growth of niche manufacturing for personalized therapies; however, supply-chain friction and policy uncertainty can still drive selective nearshoring and stronger vendor qualification efforts. In Europe, Middle East & Africa, regulatory harmonization efforts and strong public-private collaborations are creating attractive hubs for large-volume biologics and vaccine manufacturing, although localized regulatory nuances require region-specific dossier strategies and extended timelines for market entry.

Asia-Pacific presents a bifurcated landscape where mature markets sustain high-quality contract manufacturing capacity and emerging markets accelerate investments in local production to ensure sovereign supply for essential biologics and vaccines. Across all regions, cross-border collaboration remains essential, as technology providers, contract manufacturers, and developers form transnational partnerships to optimize cost, access specialist skills, and achieve scale. Talent flows, regulatory convergence, and infrastructure investments-such as logistics corridors and cold-chain networks-will therefore determine which regions become centers of excellence for particular modalities. Importantly, companies that align their footprint strategy with local incentives, skilled labor pools, and supply ecosystems will be better positioned to manage regulatory complexity and reduce time-to-clinic across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Company-level insights highlighting how pharmaceutical developers, contract manufacturers, technology providers, and system integrators are reshaping portfolios, forming strategic alliances, and optimizing manufacturing footprints to capture opportunity

Leading companies across the biomanufacturing value chain are responding to the evolving landscape by pursuing a mix of capability expansion, strategic partnerships, and targeted technology adoption. Contract manufacturing organizations are increasingly offering integrated services that span cell banking, analytical development, and commercial-scale fill-finish in order to capture greater value and reduce client time to market. Technology providers are focusing on modularization, single-use content, and digital platforms that enable remote monitoring and predictive maintenance, thereby lowering operational risk and supporting multi-site orchestration. Pharmaceutical developers are differentiating by retaining strategic control over critical steps-such as cell line development and process characterization-while outsourcing routine scale-up and high-volume production to specialized partners.

Across the ecosystem, strategic alliances and co-investment models are proliferating as a way to share development risk and accelerate access to capacity. Companies are also prioritizing investments in advanced analytics and automation to reduce batch variability, improve yield, and accelerate regulatory approvals. Talent strategies have become a point of competitive differentiation, with firms investing in cross-disciplinary training programs to bridge gaps between process development, data science, and quality assurance. Finally, corporate governance around supply resilience is evolving: executive teams now require scenario planning for tariff shocks, supplier disruptions, and rapid demand surges, and they increasingly expect portfolio managers to demonstrate supply continuity plans as part of go/no-go commercialization decisions.

Actionable strategic recommendations for industry leaders to accelerate adoption of advanced bioprocessing, secure resilient supply networks, align commercial models with regulatory evolutions, and prioritize scalable investments for long-term advantage

Industry leaders should take pragmatic, prioritized actions to secure advantage amid rapid technological and policy change. First, accelerate deployment of modular and single-use assets for early-stage and flexible commercial production to reduce time-to-deploy and lower validation overhead. This approach allows organizations to pilot innovative process modes such as perfusion or continuous chromatography within a constrained capital envelope, and then scale selectively as product economics justify larger fixed investments. Second, enhance supplier diversification and strategic sourcing agreements to mitigate tariff-related cost inflections and minimize the risk of single-source failures; in parallel, develop contingency plans that include local fabrication partners and validated secondary suppliers.

Third, invest in digital quality and process analytics to support real-time release strategies and to satisfy evolving regulatory expectations. Such capabilities shorten approval timelines and enable more efficient tech transfer across sites. Fourth, cultivate workforce resilience through structured cross-training programs that integrate process science, automation skills, and data literacy, ensuring teams can operate highly automated, multi-site networks. Fifth, adopt a selective nearshoring framework that evaluates total landed cost, regulatory alignment, and lead-time reduction benefits versus capital outlay. Finally, pursue collaborative models with academic centers and technology providers to stay at the leading edge of modalities such as cell-free systems and mRNA platforms; by doing so, leaders can capture first-mover advantages while distributing technical risk.

Transparent research methodology detailing integrated primary and secondary research, expert interviews, data triangulation, validation processes, segmentation mapping, and reproducible assessment techniques for robust market insight generation

The research methodology underpinning this analysis draws on an integrated approach that combines primary interviews, secondary literature synthesis, and rigorous triangulation to ensure robustness and reproducibility. Primary research included structured interviews with senior executives across development, manufacturing, procurement, and regulatory functions, alongside in-depth conversations with technology vendors, system integrators, and contract manufacturers. These engagements surfaced practical constraints, investment priorities, and real-world examples of technology transfer and scaling challenges. Secondary research encompassed peer-reviewed literature, public regulatory guidance documents, and technical white papers to contextualize trends and to validate technical assertions.

Data triangulation was applied to reconcile insights across sources: qualitative interview data were cross-referenced with technical specifications, procurement practices, and regulatory guidance to identify convergent themes. Segmentation logic was iteratively validated with subject-matter experts to ensure that product types, technology classes, process stages, end-user categories, operation scales, cell lines, and process modes reflect industry realities and purchasing behaviors. Finally, the methodology incorporated scenario analysis to explore how tariff shocks, supply disruptions, and rapid adoption of new process technologies could affect strategic choices. Where applicable, methodological limitations and areas for further research are documented to guide readers in interpreting the findings and applying them within their own organizational contexts.

A concise strategic conclusion synthesizing critical takeaways, risk-mitigation imperatives, investment priorities, and forward-looking considerations for stakeholders seeking to lead in next-generation biomanufacturing

In conclusion, next-generation biomanufacturing represents a strategic inflection point where technological innovation, supply-chain strategy, and regulatory adaptation converge to reshape industry economics and competitive dynamics. The maturation of continuous bioprocessing, modular facilities, single-use systems, and digital analytics creates a pathway for faster, more reliable production of complex biologics, but realizing these benefits requires intentional investment in capabilities and partnerships. Leaders must therefore align capital allocation with modality-specific needs, prioritize supplier resilience in the face of geopolitical and tariff-induced disruptions, and build cross-functional teams capable of managing automated, data-rich operations.

Looking ahead, the organizations that will succeed are those that adopt a systems view-integrating process development, regulatory strategy, and commercial planning-and that remain agile in their footprint decisions. The imperative is not only to adopt new technologies but to embed them within governance frameworks that ensure quality, reproducibility, and rapid scale-up. By combining targeted investments in flexible infrastructure, strategic supplier relationships, and workforce development, stakeholders can navigate uncertainty and capture the transformative potential of next-generation biomanufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation Biomanufacturing Market, by Product Type

  • 8.1. Cell And Gene Therapies
    • 8.1.1. Car-T Therapies
    • 8.1.2. Cell Therapies
    • 8.1.3. Gene Editing Therapies
  • 8.2. Enzymes
    • 8.2.1. Diagnostic Enzymes
    • 8.2.2. Industrial Enzymes
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Autoimmune
    • 8.3.2. Infectious Diseases
    • 8.3.3. Oncology
  • 8.4. Recombinant Proteins
    • 8.4.1. Cytokines
    • 8.4.2. Growth Factors
    • 8.4.3. Hormones
  • 8.5. Vaccines
    • 8.5.1. Live Attenuated Vaccines
    • 8.5.2. Mrna Vaccines
    • 8.5.3. Subunit Vaccines
    • 8.5.4. Viral Vector Vaccines

9. Next-Generation Biomanufacturing Market, by Technology

  • 9.1. Cell-Free Systems
    • 9.1.1. Cell-Free Expression Kits
    • 9.1.2. Cell-Free Synthesis Platforms
  • 9.2. Continuous Bioprocessing
    • 9.2.1. Continuous Chromatography
    • 9.2.2. Inline Monitoring Systems
    • 9.2.3. Perfusion Systems
  • 9.3. Modular Facilities
    • 9.3.1. Prefabricated Modules
    • 9.3.2. Skid-Mounted Systems
  • 9.4. Single-Use Systems
    • 9.4.1. Single-Use Bags
    • 9.4.2. Single-Use Bioreactors
    • 9.4.3. Single-Use Tubing And Connectors

10. Next-Generation Biomanufacturing Market, by Process Stage

  • 10.1. Downstream Processing
    • 10.1.1. Chromatography
    • 10.1.2. Filtration
    • 10.1.3. Purification
  • 10.2. Formulation
    • 10.2.1. Fill And Finish
    • 10.2.2. Lyophilization
    • 10.2.3. Packaging
  • 10.3. Upstream Processing
    • 10.3.1. Bioreactor Operation
    • 10.3.2. Cell Culture
    • 10.3.3. Media Preparation

11. Next-Generation Biomanufacturing Market, by Operation Scale

  • 11.1. Clinical Scale
  • 11.2. Commercial Scale
  • 11.3. Pilot Scale

12. Next-Generation Biomanufacturing Market, by Cell Line

  • 12.1. Cho Cell
    • 12.1.1. Cho-DG44
    • 12.1.2. Cho-K1
  • 12.2. E. Coli
    • 12.2.1. Bl21
    • 12.2.2. K12
  • 12.3. Yeast
    • 12.3.1. Pichia Pastoris
    • 12.3.2. Saccharomyces Cerevisiae

13. Next-Generation Biomanufacturing Market, by Process Mode

  • 13.1. Batch
  • 13.2. Continuous
  • 13.3. Fed Batch
  • 13.4. Perfusion

14. Next-Generation Biomanufacturing Market, by End User

  • 14.1. Academic And Research Institutions
  • 14.2. Biotech Companies
  • 14.3. Contract Manufacturing Organizations
  • 14.4. Pharmaceutical Companies

15. Next-Generation Biomanufacturing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Next-Generation Biomanufacturing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Next-Generation Biomanufacturing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Next-Generation Biomanufacturing Market

19. China Next-Generation Biomanufacturing Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Agilent Technologies, Inc.
  • 20.6. Amyris, Inc.
  • 20.7. Applikon Biotechnology BV
  • 20.8. bbi-biotech GmbH
  • 20.9. Biofluidica, Inc.
  • 20.10. Codexis, Inc.
  • 20.11. Danaher Corporation
  • 20.12. Eppendorf AG
  • 20.13. ESCO Group
  • 20.14. Eurofins Scientific SE
  • 20.15. Evolva Holding SA
  • 20.16. Evonik Industries AG
  • 20.17. GEA Group AG
  • 20.18. GENEWIZ, Inc. by Azenta Life Sciences
  • 20.19. Genomatica, Inc.
  • 20.20. Ginkgo Bioworks Holdings, Inc.
  • 20.21. Hamilton Company
  • 20.22. Illumina, Inc.
  • 20.23. Koninklijke DSM N.V.
  • 20.24. LanzaTech, Inc.
  • 20.25. Macrogen Inc.
  • 20.26. Merck KGaA
  • 20.27. Novozymes A/S
  • 20.28. Oxford Nanopore Technologies plc
  • 20.29. PBS Biotech, Inc.
  • 20.30. PerkinElmer Inc.
  • 20.31. QIAGEN N.V.
  • 20.32. Sartorius AG
  • 20.33. Shanghai Bailun Biotechnology Co., Ltd.
  • 20.34. Solaris Biotechnology Srl by DONALDSON ITALIA S.R.L.
  • 20.35. Takara Bio Inc.
  • 20.36. Thermo Fisher Scientific Inc.
  • 20.37. ZETA GmbH
  • 20.38. Zymergen Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY OPERATION SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GENE EDITING THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GENE EDITING THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GENE EDITING THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DIAGNOSTIC ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DIAGNOSTIC ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DIAGNOSTIC ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INDUSTRIAL ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INDUSTRIAL ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INDUSTRIAL ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE EXPRESSION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE EXPRESSION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE EXPRESSION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYNTHESIS PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYNTHESIS PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYNTHESIS PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INLINE MONITORING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INLINE MONITORING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INLINE MONITORING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PREFABRICATED MODULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PREFABRICATED MODULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PREFABRICATED MODULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SKID-MOUNTED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SKID-MOUNTED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SKID-MOUNTED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BAGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BAGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BAGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE TUBING AND CONNECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE TUBING AND CONNECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE TUBING AND CONNECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PURIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILL AND FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILL AND FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILL AND FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LYOPHILIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LYOPHILIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LYOPHILIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MEDIA PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MEDIA PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MEDIA PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY OPERATION SCALE, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CLINICAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CLINICAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CLINICAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PILOT SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PILOT SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PILOT SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO CELL, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO-DG44, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO-DG44, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO-DG44, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO-K1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO-K1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO-K1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY E. COLI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY E. COLI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY E. COLI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY E. COLI, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BL21, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BL21, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BL21, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY K12, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY K12, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY K12, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY YEAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY YEAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY YEAST, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PICHIA PASTORIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PICHIA PASTORIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PICHIA PASTORIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FED BATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FED BATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FED BATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY OPERATION SCALE, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO CELL, 2018-2032 (USD MILLION)
  • TABLE 242. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY E. COLI, 2018-2032 (USD MILLION)
  • TABLE 243. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY YEAST, 2018-2032 (USD MILLION)
  • TABLE 244. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 245. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY OPERATION SCALE, 2018-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 264. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO CELL, 2018-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY E. COLI, 2018-2032 (USD MILLION)
  • TABLE 266. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY YEAST, 2018-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 268. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, 2018-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 280. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCE